Building an endobariatric program: lessons learned

Abstract

The emphasis on treating obesity has never been more critical, yet the complexity of delivering care has become more intricate due to new procedures, variable insurance coverage, and inconsistent reimbursement. This is our experience building an endobariatric program and treating overweight and obese patients with endobariatric therapies (EBTs) over 3 years. The primary intention of this manuscript was to educate the reader on how to build an endobariatric program, identify barriers, and provide succinct solutions to establish a successful program. The secondary aim was weight loss outcomes of procedures offered at our institution. We compiled a list of lessons learned, based on the difficulties we experienced to make it easy for others embarking on this journey. Herein, we present a business development strategy to overcome impediments, whilst offering high quality service.

The high cost and lack of insurance coverage are significant barriers. Marketing can be costly and is often a factor that is ignored particularly early on, when finances are limited. However, it is an integral component of growing the program. The percentage total body weight loss (%TBWL) at 6 and 12 months post ESG was 17.8 ± 6.48 and 20.6 ± 8.3 (P < 0.001), respectively. The %TBWL at 6 months post IGB was 14.9 ± 9.8 for the Orbera IGB and 12.6 ± 7.4 for the Reshape IGB. There was a trend of preference for ESG compared to IGB placement over the 3 years.

The key to building a successful endobariatric program is a motivated physician leader, collaborative bariatric surgeons, institutional support, and marketing. Insurance coverage will likely occur in the near future and programs must be prepared to manage the massive influx of patients that will likely request these procedures.

Publication History

Received: 28 February 2020

Accepted: 22 May 2020

Article published online:
31 August 2020

• References

• 1 Afshin A, Forouzanfar MH, Reitsma MB. et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med 2017; 377: 13-27
• 2 Centrals for Disease Control and Prevention. adults obesity facts. 2020 www.cdc.gov/obesity/data/adult.html (Accessed 2020 May 5)
• 3 Hales CM, Carroll MD, Fryar CD. et al. Prevalence of Obesity Among Adults and Youth: United States, 2015-2016. NCHS Data Brief 2017; 288: 1-8
• 4 Acosta A, Streett S, Kroh MD. et al. White Paper AGA: POWER - Practice Guide on Obesity and Weight Management, Education, and Resources. Clinical gastroenterology and hepatology 2017; 15: 631-649
• 5 NHLBI, NIDDK. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Bethesda: National Heart, Lung, and Blood Institute; 1998
• 6 Cheskin LJ, Hill C, Adam A. et al. Endoscopic sleeve gastroplasty versus high-intensity diet and lifestyle therapy: a case-matched study. Gastrointest Endosc 2020; 91: 342-349
• 7 Courcoulas A, Dayyeh BA, Eaton L. et al. Intragastric balloon as an adjunct to lifestyle intervention: a randomized controlled trial. International journal of obesity 2017; 41: 427-433
• 8 Abu Dayyeh BK, Kumar N, Edmundowicz SA. et al. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc 2015; 82: 425-438
• 9 Hedjoudje A, Dayyeh BA, Cheskin LJ. et al. Efficacy and safety of endoscopic sleeve gastroplasty: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2020; 18: 1043-1053
• 10 Thompson CC, Dayyeh BK, Kushnir V. et al. Aspiration therapy for the treatment of obesity: 4-year results of a multicenter randomized controlled trial. Surg Obes Relat Dis 2019; 15: 1348-1354
• 11 Fayad L, Adam A, Schweitzer M. et al. Endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy: a case-matched study. Gastrointest Endosc 2019; 89: 782-788
• 12 [Anonymous] Digestive Weight Loss Center. Concierge Endoscopic Weight Loss Program.
• 13 Fung M, Wharton S, Macpherson A. et al. Receptivity to bariatric surgery in qualified patients. J Obes 2016; 2016: 5372190
• 14 Conaty EA, Bonamici NJ, Gitelis ME. et al. Efficacy of a required preoperative weight loss program for patients undergoing bariatric surgery. J Gastrointest Surg 2016; 20: 667-673
• 15 Keith JrCJ, Goss LE, Blackledge CD. et al. Insurance-mandated preoperative diet and outcomes after bariatric surgery. Surg Obes Relat Dis 2018; 14: 631-636
• 16 Yumuk V, Tsigos C, Fried M. et al. European guidelines for obesity management in adults. Obesity Facts 2015; 8: 402-424
• 17 Hill C, El Zein M, Agnihotri A. et al. Endoscopic sleeve gastroplasty: the learning curve. Endosc Int Open 2017; 5: E900-E904
• 18 Sartoretto A, Sui Z, Hill C. et al. Endoscopic sleeve gastroplasty (ESG) is a reproducible and effective endoscopic bariatric therapy suitable for widespread clinical adoption: a large, international multicenter study. Obesity Surgery 2018; 28: 1812-1821
• 19 Murino A, Arvanitakis M, Le Moine O. et al. Effectiveness of endoscopic management using selfexpandable metal stents in a large cohort of patients with post-bariatric leaks. Obesity Surgery 2015; 25: 1569-1576
• 20 [Anonymous] American Board of Obesity Medicine. https://www.abom.org/